According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
Other equities analysts have also issued research reports about the company. Canaccord Genuity set a $17.00 price objective on Gemphire Therapeutics and gave the stock a buy rating in a research note on Thursday, March 16th. Jefferies Group LLC reissued a buy rating and issued a $17.00 price objective on shares of Gemphire Therapeutics in a research note on Thursday, March 16th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Gemphire Therapeutics currently has a consensus rating of Buy and an average price target of $19.75.
Gemphire Therapeutics (NASDAQ:GEMP) opened at 11.9347 on Wednesday. Gemphire Therapeutics has a 12-month low of $7.25 and a 12-month high of $13.98. The firm’s market capitalization is $110.66 million. The company’s 50-day moving average price is $9.93 and its 200-day moving average price is $9.91.
Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings results on Wednesday, March 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.24. Equities analysts expect that Gemphire Therapeutics will post ($2.18) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Gemphire Therapeutics Inc (GEMP) Downgraded by Zacks Investment Research” was first published by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.mideasttime.com/gemphire-therapeutics-inc-gemp-downgraded-by-zacks-investment-research/1589188.html.
In other news, Director Andy Sassine bought 21,119 shares of the company’s stock in a transaction dated Friday, March 10th. The stock was bought at an average price of $9.47 per share, for a total transaction of $199,996.93. Following the completion of the transaction, the director now directly owns 136,264 shares in the company, valued at approximately $1,290,420.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Several large investors have recently added to or reduced their stakes in the company. Blue Clay Capital Management LLC purchased a new stake in Gemphire Therapeutics during the third quarter worth $131,000. Monashee Investment Management LLC bought a new stake in Gemphire Therapeutics during the third quarter worth approximately $144,000. Spark Investment Management LLC bought a new stake in Gemphire Therapeutics during the third quarter worth approximately $198,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Gemphire Therapeutics during the third quarter worth approximately $3,976,000. Institutional investors own 14.85% of the company’s stock.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.